Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain

P. G. Crosignani, A. Luciano, Amrit Ray, A. Bergqvist

Research output: Contribution to journalArticle

Abstract

Background: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain. Methods: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. Endpoints included patient response to treatment in five signs/symptoms (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, induration) and changes in bone mineral density (BMD) and productivity at 6 and 18 months. Results: DMPA-SC 104 and leuprolide produced equivalent (P <0.02) reductions in at least four pain categories and significant (P <0.001) improvements in composite score at months 6 and 18. At month 6, reductions in total hip and lumbar spine BMD were significantly less (P <0.001) with DMPA-SC 104 versus leuprolide. BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group. Total productivity also significantly (P≤0.05) improved in both groups at 6 and 18 months. Conclusions: DMPA-SC 104 reduces endometriosis-associated pain as effectively as leuprolide and improves productivity with significantly less BMD decline.

Original languageEnglish
Pages (from-to)248-256
Number of pages9
JournalHuman Reproduction
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Leuprolide
Medroxyprogesterone Acetate
Endometriosis
Pain
Bone Density
Therapeutics
Dyspareunia
Dysmenorrhea
Pelvic Pain
Subcutaneous Injections
Signs and Symptoms
Hip
Spine
Randomized Controlled Trials
Safety

Keywords

  • Bone mineral density
  • Depot medroxyprogesterone acetate
  • Endometriosis
  • Leuprolide
  • Pelvic pain
  • Subcutaneous injection

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. / Crosignani, P. G.; Luciano, A.; Ray, Amrit; Bergqvist, A.

In: Human Reproduction, Vol. 21, No. 1, 01.2006, p. 248-256.

Research output: Contribution to journalArticle

Crosignani, P. G. ; Luciano, A. ; Ray, Amrit ; Bergqvist, A. / Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. In: Human Reproduction. 2006 ; Vol. 21, No. 1. pp. 248-256.
@article{5f6408deb0004c7bb66ceae67083482c,
title = "Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain",
abstract = "Background: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain. Methods: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. Endpoints included patient response to treatment in five signs/symptoms (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, induration) and changes in bone mineral density (BMD) and productivity at 6 and 18 months. Results: DMPA-SC 104 and leuprolide produced equivalent (P <0.02) reductions in at least four pain categories and significant (P <0.001) improvements in composite score at months 6 and 18. At month 6, reductions in total hip and lumbar spine BMD were significantly less (P <0.001) with DMPA-SC 104 versus leuprolide. BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group. Total productivity also significantly (P≤0.05) improved in both groups at 6 and 18 months. Conclusions: DMPA-SC 104 reduces endometriosis-associated pain as effectively as leuprolide and improves productivity with significantly less BMD decline.",
keywords = "Bone mineral density, Depot medroxyprogesterone acetate, Endometriosis, Leuprolide, Pelvic pain, Subcutaneous injection",
author = "Crosignani, {P. G.} and A. Luciano and Amrit Ray and A. Bergqvist",
year = "2006",
month = "1",
doi = "10.1093/humrep/dei290",
language = "English",
volume = "21",
pages = "248--256",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain

AU - Crosignani, P. G.

AU - Luciano, A.

AU - Ray, Amrit

AU - Bergqvist, A.

PY - 2006/1

Y1 - 2006/1

N2 - Background: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain. Methods: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. Endpoints included patient response to treatment in five signs/symptoms (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, induration) and changes in bone mineral density (BMD) and productivity at 6 and 18 months. Results: DMPA-SC 104 and leuprolide produced equivalent (P <0.02) reductions in at least four pain categories and significant (P <0.001) improvements in composite score at months 6 and 18. At month 6, reductions in total hip and lumbar spine BMD were significantly less (P <0.001) with DMPA-SC 104 versus leuprolide. BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group. Total productivity also significantly (P≤0.05) improved in both groups at 6 and 18 months. Conclusions: DMPA-SC 104 reduces endometriosis-associated pain as effectively as leuprolide and improves productivity with significantly less BMD decline.

AB - Background: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain. Methods: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. Endpoints included patient response to treatment in five signs/symptoms (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, induration) and changes in bone mineral density (BMD) and productivity at 6 and 18 months. Results: DMPA-SC 104 and leuprolide produced equivalent (P <0.02) reductions in at least four pain categories and significant (P <0.001) improvements in composite score at months 6 and 18. At month 6, reductions in total hip and lumbar spine BMD were significantly less (P <0.001) with DMPA-SC 104 versus leuprolide. BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group. Total productivity also significantly (P≤0.05) improved in both groups at 6 and 18 months. Conclusions: DMPA-SC 104 reduces endometriosis-associated pain as effectively as leuprolide and improves productivity with significantly less BMD decline.

KW - Bone mineral density

KW - Depot medroxyprogesterone acetate

KW - Endometriosis

KW - Leuprolide

KW - Pelvic pain

KW - Subcutaneous injection

UR - http://www.scopus.com/inward/record.url?scp=29144488393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144488393&partnerID=8YFLogxK

U2 - 10.1093/humrep/dei290

DO - 10.1093/humrep/dei290

M3 - Article

C2 - 16176939

AN - SCOPUS:29144488393

VL - 21

SP - 248

EP - 256

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 1

ER -